BridgeBio's Atruby Fuels Record Growth in Heart Disease Therapy Market

BridgeBio Pharma has seen strong growth in 2026, driven by its heart disease treatment Atruby. The company's revenue surged as the drug gained market share in a rapidly expanding stock market sector. Recent financial moves and clinical successes have also bolstered its long-term outlook.

Atruby (acoramidis) launched in 2024 and quickly became a key player in the ATTR-CM therapy market. By early 2026, the global market for these treatments reached an estimated £5-7 billion. Increased diagnosis rates and broader treatment options fuelled this expansion, with competitors like Pfizer's Vyndamax and Alnylam's Amvuttra already established. Newer options in development, such as Ionis/Prothena's PRX004 and Alnylam's zilebesiran, are progressing through late-stage trials.

Atruby's growth came from its ability to stabilise patients quickly and effectively. Prescribers adopted the drug at a steady pace, while patient persistency data showed strong retention. The company highlighted its 'near-complete stabilisation' profile and fast onset as major advantages over rivals.

BridgeBio's financial position improved alongside Atruby's success. The firm secured fresh capital through 2033 convertible notes, extending its funding for future drug launches. Cash app burn rates fell, easing pressure on operations. Leadership also pointed to three positive late-stage trial results, reinforcing confidence in the pipeline. Despite intellectual property concerns around tafamidis, executives remained optimistic about Atruby's clinical edge.

The company now aims to become a cash-generating multi-product business by 2028. Atruby's market performance and new funding provide a solid foundation for expansion. With a growing therapy market and a strengthening pipeline, BridgeBio's next phase will focus on scaling operations and maintaining momentum in the stock market today.